Abstract：Objective: To observe the changes of serum interleukin-35 (IL-35) and C-C motif chemokine ligand 19 (CCL19) in children with systemic lupus erythematosus (SLE), and to analyze the association with immunological indexes. Methods: A total of 97 children with SLE in the hospital were included from January 2022 to March 2024, and 97 healthy children were selected for control study during the same time period. The changes of serum IL-35 and CCL19 levels were observed, and the correlation with immunological indexes [including anti-ds-DNA antibody, immunoglobulin (Ig), complements C3 and C4] was analyzed. Results: Compared with the healthy children, the children with SLE had a significantly lower serum IL-35 level and a significantly higher serum CCL19 level (P<0.05). Compared with the children with inactive SLE, serum levels of IL-35, C3, and C4 in the children with active SLE were significantly lower while serum levels of CCL19, anti-ds-DNA antibody, IgM, IgG, and IgA were significantly higher (P<0.05). Pearson correlation analysis showed that the serum level of IL-35 in children with SLE was negatively correlated with the levels of anti-ds-DNA antibody, IgM, IgG, and IgA, and was positively correlated with the levels of C3 and C4 (P<0.05). Serum CCL19 level was positively correlated with the levels of anti-ds-DNA antibody, IgM, IgG and IgA, and was negatively correlated with the levels of C3 and C4 in children with SLE (r=-0.314, -0.203, -0.301, -0.201, 0.318, 0.383, P<0.05). Linear regression analysis suggested that anti-ds-DNA antibody had a negative impact on IL-35 level in children with SLE (r=0.272, 0.209, 0.362, 0.202, -0.219, -0.391,P<0.05) while C3 had a positive impact on IL-35 level (P<0.05). IgG in children with SLE had a positive impact on CCL19 level (P<0.05). Conclusion: The abnormal changes of serum IL-35 and CCL19 levels in children with SLE are correlated with the levels of anti-ds-DNA antibody, IgM, IgG and IgA. There is a certain influence relationship between anti-ds-DNA antibody, C3 and IL-35, IgG and CCL19.
[1] Cann MP,Sage AM,McKinnon E,et al.Childhood systemic lupus erythematosus: presentation,management and long-term outcomes in an australian cohort[J].Lupus,2022,31(2):246-255. [2] Alexander T,Hedrich CM.Systemic lupus erythematosus-are children small adults[J].Z Rheumatol,2022,81(1):28-35. [3] Bahadorian D,Faraj TA,Kheder RK,et al.A glance on the role of IL-35 in systemic lupus erythematosus (SLE)[J].Cytokine,2024(176):156501. [4] Drner T,Tanaka Y,Dow ER,et al.Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus[J].Ann Rheum Dis,2022,81(9):1267-1272. [5] Zucchi D,Silvagni E,Elefante E,et al.Systemic lupus erythematosus: one year in review 2023[J].Clin Exp Rheumatol,2023,41(5):997-1008. [6] Accapezzato D,Caccavale R,Paroli MP,et al.Advances in the pathogenesis and treatment of systemic lupus erythematosus[J].Int Mol Sci,2023,24(7):6578. [7] Nassif MA.Urine and serum interleukin 35 as potential biomarkers of lupus nephritis[J].Cent Eur J Immunol,2021,46(3):351-359. [8] Ye C,Yano H,Workman CJ,et al.Interleukin-35: structure,function and its impact on immune-related diseases[J].Interferon Cytokine Res,2021,41(11):391-406. [9] Zhu ZZ,Chen XH,Wei SR,et al.Role of CD19+ CD5+ CD1d+ bregs in maintaining the Th17/Treg balance in mice with systemic lupus erythematosus complicated with atherosclerosis[J].Int Rheum Dis,2023,26(6):1048-1057. [10] Cai Z,Zhang S,Wu P,et al.A novel potential target of IL-35-regulated JAK/STAT signaling pathway in lupus nephritis[J].Clin Transl Med,202,11(2):309. [11] 彭子辉,程井军,李红涛,等.ADA、CCL19在系统性红斑狼疮患者中的表达水平及临床意义[J].国际检验医学杂志,2022,43(14):1755-1760. [12] Xie Y,Zhang H,Huang J,et al.Interleukin-35 in autoimmune dermatoses: current concepts[J].Open Med (Wars),2022,17(1):589-600. [13] 张绍君,李俊巧,张永刚,等.系统性红斑狼疮患者血清PS-PLA1、CCL19水平与疾病活动度及免疫功能的相关性分析[J].疑难病杂志,2020,19(11):1143-1146,1156.
2024, Vol. 30 
冀公网安备13080202000677号